RxDoctor Payments Data

Betty Grant-Anderson, MD

Cardiovascular Disease · Hemet, CANPI 1992723514

Payments from drug & device makers

$5,387in general payments, 2019–2025

Across 375 payments — averaging $14.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$2K
  • Novartis$541
  • Johnson & Johnson$405
  • Boehringer Ingelheim$376
  • E.r. Squibb & Sons, L.L.C.$354
  • Merck$342
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$5,22397%
  • Education$1643%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,387 in reported general payments places this provider in the 60th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$90,173
Medicare patients
350
Services billed
928

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban62$64,699
EntrestoSacubitril/Valsartan26$30,719
Ranolazine ErRanolazine26$2,025
Metoprolol Succinate101$1,524
Losartan Potassium62$732
Carvedilol43$474
Isosorbide Mononitrate ErIsosorbide Mononitrate34$450
Furosemide46$336
Digoxin11$271
Amiodarone Hcl20$249
Amlodipine Besylate22$246
Lisinopril22$233
ClopidogrelClopidogrel Bisulfate21$211
Esomeprazole Magnesium13$203
Hydralazine Hcl15$201

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$102$64,69962 claims
NovartisEntresto$541$30,71926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Hemet

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →